Clinical Trial Recruiting patient

Clinical Trial Recruiting patient

Recruiting Patients in Ongoing Studies Contact Detail: +91-9983656667, +91-9828683771, +91-9414362711 e-mail: bmchrcclinicaltrial@gmail.com whatsup No. 91-9828683771

No. Ongoing Studies Principal Investigator Since Dated
1 Title of study: Bayer 21140 – A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC) Dr. Pawan Agarwal Mar-2021
2 Protocol ID: A5481145 Version 1.0 Dated 19 OCT 2020 Protocol Title: “Treatment patterns and clinical outcomes among Indian patients receiving Palbociclib combinations for HR+/HER2- Advanced/Metastatic breast cancer in real world settings Dr. Ajay Bapna April 2021
3 A prospective, multicenter, open label single arm Phase IV clinical trial to assess safety of ImbruvicaTM (Ibrutinib capsules 140 mg) in Indian patients with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion Dr. Upendra Sharma Dec-2019
4 Protocol LEE011A2207 Ref: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease Dr. Ajay Bapna Jan-2020
5 Ref No. “An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease CLEE011A2404. Dr. Ajay Bapna Oct-2019
6 Ref:A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1). Dr. Aseem K Samar Oct-2019